| 报告期指标 | 2024年年报 | 2023年年报 | 本年比上年增减(%) | 2022年年报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | 0.7400 | 0.7400 | 0 | 1.2400 | | 每股净资产（元） | 0 | 8.72 | -100 | 8.12 | | 每股公积金(元) | 1.57 | 1.58 | -0.63 | 1.22 | | 每股未分配利润(元) | 6.06 | 5.67 | 6.88 | 5.47 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 419.76 | 409.41 | 2.53 | 418.13 | | 净利润(亿元) | 3.8 | 3.81 | -0.26 | 6.1 | | 净资产收益率(%) | 8.16 | 8.79 | -7.17 | 15.82 | 数据四舍五入，查看更多财务数据>> 一、主要会计数据和财务指标 | 名称 | 持有数量(万股) | 占总股本比例(%) | 增减情况(万股) | | --- | --- | --- | --- | ...

Dividend Distribution - The company plans to distribute a cash dividend of 3.00 RMB per 10 shares (including tax) to all shareholders[6]. - The company has a profit distribution plan for 2024, proposing a cash dividend of RMB 3.00 per 10 shares, pending approval at the shareholders' meeting[176]. - The company’s cash dividend policy aligns with its articles of association and has been approved by independent directors[174]. Business Transformation and Strategy - The company has undergone a significant business transformation, shifting its main products to include agricultural supplies and automotive services, while still engaging in pharmaceutical sales[22]. - The company focuses on modern agricultural services, aiming to become a leading comprehensive service provider in China, leveraging global resources and innovative technology[47]. - The company plans to focus on agricultural services and modern agricultural technology to support rural revitalization and agricultural development[117]. Financial Performance - The company's operating revenue for 2024 reached ¥41,976,296,857, representing a 2.53% increase compared to ¥40,941,153,868 in 2023[6]. - The net profit attributable to shareholders for 2024 was ¥380,119,319.55, showing a slight decrease of 0.22% from ¥380,944,589.50 in 2023[6]. - The total assets at the end of 2024 were ¥18,511,697,095, reflecting an 8.87% decrease from ¥20,313,353,249 at the end of 2023[24]. Risk Management - The company emphasizes the importance of risk factors such as changes in industrial policies, intensified market competition, and shifts in customer demand[5]. - The company faces market, credit, operational, and legal risks in its hedging activities, which are actively managed[99]. - The company acknowledges potential risks, including changes in industry policies that could impact its main products and operations[125]. Agricultural Sector Insights - The agricultural service sector is expected to benefit from policies aimed at enhancing food security and rural modernization[34]. - The agricultural input circulation industry in China is characterized by a fragmented market with a significant presence of supply and marketing cooperative companies, which dominate the sector[36]. - The national grain production is projected to reach 1.4 trillion jin in 2024, reinforcing the foundation of food security in China[37]. Automotive Market Insights - The automotive market in China is expected to sell 31.44 million vehicles in 2024, representing a year-on-year growth of 4.5%[42]. - The penetration rate of new energy vehicles in China is projected to reach 40.9% in 2024, marking a significant increase of 9.35 percentage points from the previous year[44]. - The automotive trading service revenue decreased by 13.11% to CNY 13.64 billion, accounting for 32.49% of total revenue[70]. Pharmaceutical Sector Insights - The pharmaceutical distribution market is experiencing consolidation, with leading companies acquiring local distributors, resulting in increased industry concentration[45]. - The company’s pharmaceutical sales business ranks among the top 100 nationwide in both wholesale and retail sectors, with a focus on traditional Chinese medicine[52]. - The government policies are continuously supporting the rapid development of the traditional Chinese medicine industry, presenting significant growth opportunities for the company[46]. Corporate Governance - The company has established a clear division of responsibilities among the shareholders' meeting, board of directors, supervisory board, and management, ensuring efficient operation and protection of shareholder interests[135]. - The board of directors consists of 9 members, including 3 independent directors, and is supported by four specialized committees: strategy, nomination, compensation and assessment, and audit[136]. - The company has strictly adhered to information disclosure obligations, ensuring that all information is true, accurate, and complete, with no instances of misleading statements or omissions[137]. Employee and Management Structure - The total number of employees at the end of the reporting period was 6,242, with 2,302 in sales and 1,241 in technical roles[169]. - The company has implemented a comprehensive training program aimed at enhancing employee skills and overall management capabilities[171]. - The company has established a performance evaluation system linked to operational development needs[159]. Investment and R&D - The company is investing 50 million RMB in R&D for new technologies aimed at improving operational efficiency[155]. - Research and development (R&D) expenses increased by 10.62% to ¥20.78 million, maintaining a stable ratio of 0.05% of total revenue[83]. - The company is exploring potential acquisitions to enhance its product portfolio and market reach[156]. Environmental and Social Responsibility - The company actively participated in the recovery of agricultural plastic pollution, recycling hundreds of tons of waste agricultural packaging and films in 2024[194]. - The company’s agricultural projects achieved a 15% reduction in fertilizer and pesticide usage, a 20% reduction in labor, and a 20% decrease in carbon emissions[192]. - The company provided various public welfare services, including free blood pressure measurements and consumer rights consultations[193]. Financial Controls and Compliance - The internal control evaluation report indicated that 100% of the total assets and operating income of the evaluated units were included in the consolidated financial statements[183]. - The company reported zero significant deficiencies in financial reporting internal controls[184]. - The internal control audit report received a standard unqualified opinion, indicating effective financial reporting internal controls as of December 31, 2024[185].

Financial Performance - The company's revenue for Q1 2025 was ¥10,190,719,678.99, representing a 3.25% increase compared to ¥9,870,220,383.50 in the same period last year[4] - Net profit attributable to shareholders was ¥58,489,901.37, up 2.40% from ¥57,119,269.17 year-on-year[4] - The net cash flow from operating activities significantly improved to ¥873,995,896.12, a 288.75% increase from -¥463,039,671.95 in the previous year[4] - The company reported a decrease of 8.19% in net profit after deducting non-recurring gains and losses, amounting to ¥45,622,928.36 compared to ¥49,693,072.45 in the same period last year[4] - The basic and diluted earnings per share remained stable at ¥0.11, unchanged from the previous year[4] - The weighted average return on equity slightly decreased to 1.23% from 1.25% year-on-year[4] - The company's net profit for the current period is 132,520,143.26, an increase of 29% compared to 102,757,658.32 in the previous period[17] - The company reported a total comprehensive income of 131,418,025.50, compared to 89,997,430.76 in the previous period, reflecting a growth of 46%[17] - The company has seen a decrease in other comprehensive income, with a net amount of -1,102,117.76 compared to -12,760,227.56 in the previous period[17] Assets and Liabilities - Total assets increased by 19.10% to ¥22,046,818,664.83 from ¥18,511,697,095.66 at the end of the previous year[4] - The total assets of the company reached CNY 22,046,818,664.83, up from CNY 18,511,697,095.66, indicating a growth of 19.83%[15] - The total liabilities increased to CNY 14,458,742,343.53 from CNY 11,024,747,591.44, reflecting a rise of 31.88%[14] Cash Flow and Investments - The company's cash and cash equivalents increased to CNY 4,266,324,370.17 from CNY 3,548,115,234.85, representing a growth of 20.24%[13] - The cash and cash equivalents at the end of the period stand at 2,354,048,830.60, an increase from 3,165,905,191.41 at the end of the previous period[19] - Investment activities resulted in a net cash outflow of -691,855,364.69, worsening from -306,633,338.58 in the previous period[18] - Financing activities generated a net cash inflow of 96,243,834.85, down from 526,658,142.44 in the previous period[19] - The company reported an investment income of CNY 6,716,676.08, a significant recovery from a loss of CNY 3,024,748.15 in the previous period[16] - The company’s long-term investments increased to CNY 173,583,082.78 from CNY 163,963,334.21, showing a growth of 5.83%[13] Business Segments - The agricultural service business saw significant growth in both sales volume and revenue, contributing to an increase in market share[7] - The automotive trading service segment faced challenges but managed to maintain performance by focusing on high-end brands and lean management[7] Future Outlook - The company plans to continue expanding its market presence and investing in new technologies, although specific figures were not disclosed in the conference call[16] - The company continues to focus on expanding its market presence and enhancing product development strategies[20]

证券代码：002758 证券简称：浙农股份 公告编号：2025-006 号 浙农集团股份有限公司 关于股份回购进展情况的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 浙农集团股份有限公司（以下简称"公司"）于 2024 年 9 月 13 日召开第五 届董事会第七次会议和第五届监事会第七次会议，审议通过了《关于股份回购方 案的议案》，同意公司以集中竞价交易方式回购部分公司已发行的人民币普通股 （A 股）股票，用于实施股权激励计划或员工持股计划。本次回购股份的资金总 额不低于人民币 1 亿元（含）且不超过人民币 2 亿元（含），回购股份价格不超 过人民币 11.14 元/股（含）。回购股份的实施期限为自公司董事会审议通过本次 回购股份方案之日起 12 个月内。具体内容详见 2024 年 9 月 14 日、2024 年 9 月 20 日公司在《证券时报》《证券日报》和巨潮资讯网（www.cninfo.com.cn）披 露的《关于股份回购方案的公告》（公告编号：2024-038）、《回购股份报告书》 （公告编号：2024-040）。 根据《上市公司股份回购规则 ...

人民财讯3月20日电，企查查APP显示，近日，浙农中药（金华）有限公司成立，法定代表人为周建 富，注册资本为2000万元，经营范围包含：药品批发；中药饮片代煎服务；食品销售；保健用品（非食 品）销售；货物进出口；第一类医疗器械销售等。 企查查股权穿透显示，该公司由浙农股份旗下浙江浙农中药科技有限公司、金华金农供销有限公司共同 持股。 ...

证券代码：002758 证券简称：浙农股份 公告编号：2025-005 号 公司回购股份的时间、数量、回购股份价格及集中竞价交易的委托时段等均 符合《深圳证券交易所上市公司自律监管指引第 9 号——回购股份》的相关规定， 具体说明如下： 根据《上市公司股份回购规则》《深圳证券交易所上市公司自律监管指引第 9 号——回购股份》等有关规定，公司应当在回购期间每个月的前三个交易日内 披露截至上月末的回购进展情况。现将公司截至上月末的回购股份进展情况公告 如下： 一、回购股份的进展情况 截至 2025 年 2 月 28 日，公司通过股份回购专用证券账户以集中竞价方式回 购公司股份数量为 11,854,062 股，占公司总股本比例 2.27%，最高成交价为 8.70 元/股，最低成交价为 7.19 元/股，成交总金额 100,170,699.25 元（不含交易费用）。 本次回购符合公司回购股份方案及相关法律法规的要求。 二、其他说明 浙农集团股份有限公司 关于股份回购进展情况的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 浙农集团股份有限公司（以下简称"公司"） ...

证券代码：002758 证券简称：浙农股份 公告编号：2025-004 号 浙农集团股份有限公司 关于股份回购进展情况的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 浙农集团股份有限公司（以下简称"公司"）于 2024 年 9 月 13 日召开第五 届董事会第七次会议和第五届监事会第七次会议，审议通过了《关于股份回购方 案的议案》，同意公司以集中竞价交易方式回购部分公司已发行的人民币普通股 （A 股）股票，用于实施股权激励计划或员工持股计划。本次回购股份的资金总 额不低于人民币 1 亿元（含）且不超过人民币 2 亿元（含），回购股份价格不超 过人民币 11.14 元/股（含）。回购股份的实施期限为自公司董事会审议通过本次 回购股份方案之日起 12 个月内。具体内容详见 2024 年 9 月 14 日、2024 年 9 月 20 日公司在《证券时报》《证券日报》和巨潮资讯网（www.cninfo.com.cn）披 露的《关于股份回购方案的公告》（公告编号：2024-038）、《回购股份报告书》 （公告编号：2024-040）。 根据《上市公司股份回购规则 ...

本次回购股份资金来源为公司自有资金，回购价格未超过上限 11.14 元/股。 本次回购符合相关法律法规及公司既定回购方案的相关规定。 证券代码：002758 证券简称：浙农股份 公告编号：2025-002 号 浙农集团股份有限公司 关于回购股份比例达到 2%的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 浙农集团股份有限公司（以下简称"公司"）于 2024 年 9 月 13 日召开第五 届董事会第七次会议和第五届监事会第七次会议，审议通过了《关于股份回购方 案的议案》，同意公司使用自有资金以集中竞价交易方式回购部分公司已发行的 人民币普通股（A 股）股票，用于实施股权激励计划或员工持股计划。本次回购 股份的资金总额不低于人民币 1 亿元（含）且不超过人民币 2 亿元（含），回购 股份价格不超过人民币 11.14 元/股（含）。回购股份的实施期限为自公司董事会 审议通过本次回购股份方案之日起 12 个月内。具体内容详见 2024 年 9 月 14 日 公司在《证券时报》《证券日报》和巨潮资讯网（www.cninfo.com.cn）披露的 《关于股份回购方 ...

证券代码：002758 证券简称：浙农股份 公告编号：2025-002 号 浙农集团股份有限公司 关于股份回购进展情况的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 浙农集团股份有限公司（以下简称"公司"）于 2024 年 9 月 13 日召开第五 届董事会第七次会议和第五届监事会第七次会议，审议通过了《关于股份回购方 案的议案》，同意公司使用自有资金以集中竞价交易方式回购部分公司已发行的 人民币普通股（A 股）股票，用于实施股权激励计划或员工持股计划。本次回购 股份的资金总额不低于人民币 1 亿元（含）且不超过人民币 2 亿元（含），回购 股份价格不超过人民币 11.14 元/股（含）。回购股份的实施期限为自公司董事会 审议通过本次回购股份方案之日起 12 个月内。具体内容详见 2024 年 9 月 14 日、 2024 年 9 月 20 日 公 司 在 《 证 券 时 报 》 《 证 券 日 报 》 和 巨 潮 资 讯 网 （www.cninfo.com.cn）披露的《关于股份回购方案的公告》（公告编号：2024-038）、 《回购股份报告书》（公 ...

浙农集团股份有限公司 关于 2021 年限制性股票激励计划部分限制性股票 回购注销完成的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 重要内容提示： 浙农集团股份有限公司（以下简称"公司"）2021 年限制性股票激励计 划（以下简称"本激励计划"）本次回购注销的限制性股票数量为 148,500 股， 占回购注销前公司总股本的 0.03%。本次回购注销涉及 25 名激励对象，其中 63,000 股限制性股票回购价格为 4.77 元/股，85,500 股限制性股票回购价格为 4.47 元/股。本次回购注销完成后，公司股份总数由 521,547,799 股减至 521,399,299 股。 截至 2024 年 12 月 30 日，上述限制性股票已在中国证券登记结算有限 责任公司深圳分公司办理完成注销手续。 一、本激励计划已履行的决策程序和信息披露情况 证券代码：002758 证券简称：浙农股份 公告编号：2025-01 号 1、2021 年 12 月 23 日，公司召开第四届董事会第十八次会议，审议通过了 《关于公司<2021 年限制性股票激励计划（草案）> ...